Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Camlin Fine Chemicals Not To Divest API Stakes
Camlin Fine Chemicals of Camlin, the maker of a popular range of stationery products, said it does not have plans to sell the API business, clarifying the announcement
Camlin Fine Chemicals of Camlin, the maker of a popular range of stationery products, said it does not have plans to sell the API business, clarifying the announcement
Alimera Sciences has reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien. The 36-month, open-label, phase 2 study, running
Scarab Genomics has introduced ScarabXpress, the latest strain in the multiple-deletion series (MDS) of its Clean Genome E coli. Based on the MDS42 strain, ScarabXpress T7lac contains a
Keryx Biopharmaceuticals has announced updated clinical results from a phase 2 study of KRX-0401 (perifosine), the company’s PI3K/Akt pathway inhibitor for cancer, as a single-agent treatment for advanced
InterMune has announced that its partner Roche has begun dosing in a phase 1b multiple ascending dose (MAD) study of ITMN-191 (RG7227) boosted by low-dose ritonavir in patients
Dynavax Technologies has announced the initiation of a phase 3 registration trial for Heplisav hepatitis B vaccine in individuals with chronic kidney disease. A second registration trial, a
SeraCare Life Sciences has announced that the company has been awarded two new contracts from the Centers for Disease Control (CDC) and the National Institutes of Health (NIH)
Hovione’s API manufacturing plant in Loures, Portugal has successfully passed a pre-approval inspection by FDA. The inspection lasted 5 days starting on 21st September and concluded on the
Cordis has announced that it has reached an agreement with Boston Scientific resolving its Palmaz infringement suit relating to Boston’s NIR stent. Cordis also settled several other cardiology-related
Boston Scientific has announced the settlement of more than a dozen lawsuits involving Johnson & Johnson, including the Palmaz-NIR suit. The company said that all the disputes involved